- Home
- VTGN vs RAND Comparison
VTGN vs RAND Comparison
Compare VTGN & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- RAND
- Stock Information
- Founded
- VTGN 1998
- RAND 1969
- Country
- VTGN United States
- RAND United States
- Employees
- VTGN N/A
- RAND N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- VTGN Health Care
- RAND Finance
- Exchange
- VTGN Nasdaq
- RAND Nasdaq
- Market Cap
- VTGN 62.9M
- RAND 57.6M
- IPO Year
- VTGN N/A
- RAND N/A
- Fundamental
- Price
- VTGN $2.26
- RAND $18.25
- Analyst Decision
- VTGN
- RAND
- Analyst Count
- VTGN 0
- RAND 0
- Target Price
- VTGN N/A
- RAND N/A
- AVG Volume (30 Days)
- VTGN 96.9K
- RAND 5.5K
- Earning Date
- VTGN 06-10-2025
- RAND 05-05-2025
- Dividend Yield
- VTGN N/A
- RAND 6.36%
- EPS Growth
- VTGN N/A
- RAND 39.63
- EPS
- VTGN N/A
- RAND 3.12
- Revenue
- VTGN $698,000.00
- RAND $8,499,970.00
- Revenue This Year
- VTGN N/A
- RAND N/A
- Revenue Next Year
- VTGN N/A
- RAND N/A
- P/E Ratio
- VTGN N/A
- RAND $5.79
- Revenue Growth
- VTGN N/A
- RAND 12.52
- 52 Week Low
- VTGN $1.90
- RAND $13.94
- 52 Week High
- VTGN $4.75
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- VTGN 47.92
- RAND 43.95
- Support Level
- VTGN $2.25
- RAND $18.02
- Resistance Level
- VTGN $2.38
- RAND $19.66
- Average True Range (ATR)
- VTGN 0.12
- RAND 0.76
- MACD
- VTGN 0.02
- RAND -0.00
- Stochastic Oscillator
- VTGN 45.71
- RAND 44.87
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.